Marie E. Fallon - 24 Jan 2022 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Chief Accounting Officer
Signature
/s/ Karen Tepichin, Attorney-in-fact
Issuer symbol
DNA
Transactions as of
24 Jan 2022
Net transactions value
$0
Form type
4
Filing time
26 Jan 2022, 17:42:11 UTC
Previous filing
07 Oct 2022
Next filing
14 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Award $0 +40,000 $0.000000 40,000 24 Jan 2022 Class B Common Stock 40,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Class B Common Stock.
F2 The RSUs vest as follows: 5% of the underlying shares on January 1, 2023; 12 monthly installments of 0.83% of the underlying shares thereafter; 12 monthly installments of 1.25% of the underlying shares thereafter; 24 monthly installments of 1.67% of the underlying shares thereafter; and 12 monthly installments of 2.5% of the underlying shares thereafter.

Remarks:

Chief Accounting Officer